GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » Total Receivables

Aptamer Group (LSE:APTA) Total Receivables : £0.14 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group Total Receivables?

Aptamer Group's Total Receivables for the quarter that ended in Dec. 2023 was £0.14 Mil.


Aptamer Group Total Receivables Historical Data

The historical data trend for Aptamer Group's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Total Receivables Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
Total Receivables
0.45 0.37 1.15 0.50

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial 1.37 1.15 1.21 0.50 0.14

Aptamer Group Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Aptamer Group Total Receivables Related Terms

Thank you for viewing the detailed overview of Aptamer Group's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group (LSE:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines